CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,696,438 | -15.8% | 59,406 | +4.2% | 0.52% | -12.9% |
| Q2 2023 | $3,202,113 | +33.8% | 57,038 | +7.8% | 0.60% | +25.4% |
| Q1 2023 | $2,392,531 | +64.2% | 52,897 | +47.6% | 0.48% | +51.1% |
| Q4 2022 | $1,457,262 | +380.9% | 35,849 | +672.8% | 0.32% | +356.5% |
| Q3 2022 | $303,000 | +11.0% | 4,639 | +3.3% | 0.07% | +16.9% |
| Q2 2022 | $273,000 | +17.7% | 4,489 | +21.4% | 0.06% | +37.2% |
| Q1 2022 | $232,000 | +1.3% | 3,699 | +80.5% | 0.04% | 0.0% |
| Q3 2021 | $229,000 | -31.0% | 2,049 | 0.0% | 0.04% | -31.7% |
| Q2 2021 | $332,000 | +24.3% | 2,049 | -6.7% | 0.06% | +12.5% |
| Q1 2021 | $267,000 | +0.8% | 2,195 | +26.8% | 0.06% | -15.2% |
| Q4 2020 | $265,000 | +13.7% | 1,731 | -37.8% | 0.07% | -4.3% |
| Q3 2020 | $233,000 | -2.5% | 2,781 | -14.5% | 0.07% | -16.9% |
| Q2 2020 | $239,000 | – | 3,251 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |